← Back to patent-cliff list
Gabapentin/nabilone (PleoPharma)
Tier C — Watch / tradeGabapentin/nabilone (PleoPharma)
PleoPharma Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CACNA1B, CACNA2D2, CB
Indications (approved)：药物戒断综合征, Substance-related disorder
Regional status
US
Phase III
2026-06-17
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Gabapentin/nabilone (PleoPharma)?
Approved indications include: 药物戒断综合征, Substance-related disorder.
When does the Gabapentin/nabilone (PleoPharma) patent expire?
No public expiry year is available for Gabapentin/nabilone (PleoPharma) yet; this page updates once verified.
How do I get a quote for Gabapentin/nabilone (PleoPharma) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01